Search Results - "Russell, J. Martin"

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial by Parker, Christopher C, James, Nicholas D, Brawley, Christopher D, Clarke, Noel W, Hoyle, Alex P, Ali, Adnan, Ritchie, Alastair W S, Attard, Gerhardt, Chowdhury, Simon, Cross, William, Dearnaley, David P, Gillessen, Silke, Gilson, Clare, Jones, Robert J, Langley, Ruth E, Malik, Zafar I, Mason, Malcolm D, Matheson, David, Millman, Robin, Russell, J Martin, Thalmann, George N, Amos, Claire L, Alonzi, Roberto, Bahl, Amit, Birtle, Alison, Din, Omar, Douis, Hassan, Eswar, Chinnamani, Gale, Joanna, Gannon, Melissa R, Jonnada, Sai, Khaksar, Sara, Lester, Jason F, O'Sullivan, Joe M, Parikh, Omi A, Pedley, Ian D, Pudney, Delia M, Sheehan, Denise J, Srihari, Narayanan Nair, Tran, Anna T H, Parmar, Mahesh K B, Sydes, Matthew R

“…Based on previous findings, we hypothesised that radiotherapy to the prostate would improve overall survival in men with metastatic prostate cancer, and that…”
Get full text

Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial by Dearnaley, David P, Prof, Jovic, Gordana, PhD, Syndikus, Isabel, FRCR, Khoo, Vincent, FRCR, Cowan, Richard A, FRCR, Graham, John D, FRCR, Aird, Edwin G, PhD, Bottomley, David, FRCR, Huddart, Robert A, FRCR, Jose, Chakiath C, FRANZCR, Matthews, John H L, FRANZCR, Millar, Jeremy L, FRANZCR, Murphy, Claire, BSc, Russell, J Martin, FRCR, Scrase, Christopher D, FRCR, Parmar, Mahesh K B, Prof, Sydes, Matthew R, MSc

“…Summary Background The aim of this trial was to compare dose-escalated conformal radiotherapy with control-dose conformal radiotherapy in patients with…”
Get full text

Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial by Dearnaley, David P, Dr, Sydes, Matthew R, CStat, Graham, John D, FRCR, Aird, Edwin G, PhD, Bottomley, David, FRCR, Cowan, Richard A, FRCR, Huddart, Robert A, FRCR, Jose, Chakiath C, FRACR, Matthews, John HL, FRACR, Millar, Jeremy, FRACR, Moore, A Rollo, MSc, Morgan, Rachel C, MSc, Russell, J Martin, FRCR, Scrase, Christopher D, FRCR, Stephens, Richard J, Syndikus, Isabel, FRCR, Parmar, Mahesh KB, DPhil

“…Summary Background In men with localised prostate cancer, conformal radiotherapy (CFRT) could deliver higher doses of radiation than does standard-dose…”
Get full text

Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data by Clarke, Caroline S, Hunter, Rachael M, Gabrio, Andrea, Brawley, Christopher D, Ingleby, Fiona C, Dearnaley, David P, Matheson, David, Attard, Gerhardt, Rush, Hannah L, Jones, Rob J, Cross, William, Parker, Chris, Russell, J Martin, Millman, Robin, Gillessen, Silke, Malik, Zafar, Lester, Jason F, Wylie, James, Clarke, Noel W, Parmar, Mahesh K B, Sydes, Matthew R, James, Nicholas D

“…Adding abiraterone acetate (AA) plus prednisolone (P) to standard of care (SOC) improves survival in newly diagnosed advanced prostate cancer (PC) patients…”
Get full text

Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial by James, Nicholas D, Prof, Sydes, Matthew R, CSci, Mason, Malcolm D, Prof, Clarke, Noel W, Prof, Anderson, John, MD, Dearnaley, David P, Prof, Dwyer, John, FRIC, Jovic, Gordana, PhD, Ritchie, Alastair WS, FRCSEd, Russell, J Martin, FRCR, Sanders, Karen, BSc, Thalmann, George N, Prof, Bertelli, Gianfilippo, MD, Birtle, Alison J, FRCR, O'Sullivan, Joe M, Prof, Protheroe, Andrew, PhD, Sheehan, Denise, FRCR, Srihari, Narayanan, FRCR, Parmar, Mahesh KB, Prof

“…Summary Background Long-term hormone therapy alone is standard care for metastatic or high-risk, non-metastatic prostate cancer. STAMPEDE—an international,…”
Get full text

Real‐world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer by Rulach, Robert J., McKay, Stephen, Neilson, Sam, White, Lillian, Wallace, Jan, Carruthers, Ross, Lamb, Carolynn, Cascales, Almudena, Marashi, Husam, Glen, Hilary, Venugopal, Balaji, Sadoyze, Azmat, Sidek, Norma, Russell, J. Martin, Alhasso, Abdulla, Dodds, David, Laskey, Jennifer, Jones, Robert J., MacLeod, Nicholas

“…Objectives To investigate the uptake, safety and efficacy of docetaxel chemotherapy in hormone‐naïve metastatic prostate cancer (mPC) in the first year of use…”
Get full text

Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019) by James, Nicholas David, Spears, Melissa R, Clarke, Noel W, Dearnaley, David P, De Bono, Johann S, Gale, Joanna, Hetherington, John, Hoskin, Peter J, Jones, Robert J, Laing, Robert, Lester, Jason F, McLaren, Duncan, Parker, Christopher C, Parmar, Mahesh K.B, Ritchie, Alastair W.S, Russell, J. Martin, Strebel, Räto T, Thalmann, George N, Mason, Malcolm D, Sydes, Matthew R

“…Abstract Background Prostate cancer (PCa) is the second most common disease among men worldwide. It is important to know survival outcomes and prognostic…”
Get full text

Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial by Rush, Hannah L, Murphy, Laura, Morgans, Alicia K, Clarke, Noel W, Cook, Adrian D, Attard, Gerhardt, Macnair, Archie, Dearnaley, David P, Parker, Christopher C, Russell, J Martin, Gillessen, Silke, Matheson, David, Millman, Robin, Brawley, Christopher D, Pugh, Cheryl, Tanguay, Jacob S, Jones, Robert J, Wagstaff, John, Rudman, Sarah, O'Sullivan, Joe M, Gale, Joanna, Birtle, Alison, Protheroe, Andrew, Gray, Emma, Perna, Carla, Tolan, Shaun, McPhail, Neil, Malik, Zaf I, Vengalil, Salil, Fackrell, David, Hoskin, Peter, Sydes, Matthew R, Chowdhury, Simon, Gilbert, Duncan C, Parmar, Mahesh K B, James, Nicholas D, Langley, Ruth E

“…Docetaxel and abiraterone acetate plus prednisone or prednisolone (AAP) both improve survival when commenced alongside standard of care (SOC) androgen…”
Get full text

Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476) by James, Nicholas D., Clarke, Noel W., Cook, Adrian, Ali, Adnan, Hoyle, Alex P., Attard, Gerhardt, Brawley, Christopher D., Chowdhury, Simon, Cross, William R., Dearnaley, David P., Bono, Johann S., Diaz‐Montana, Carlos, Gilbert, Duncan, Gillessen, Silke, Gilson, Clare, Jones, Rob J., Langley, Ruth E., Malik, Zafar I., Matheson, David J., Millman, Robin, Parker, Chris C., Pugh, Cheryl, Rush, Hannah, Russell, J. Martin, Berthold, Dominik R., Buckner, Michelle L., Mason, Malcolm D., Ritchie, Alastair W. S., Birtle, Alison J., Brock, Susannah J., Das, Prantik, Ford, Dan, Gale, Joanna, Grant, Warren, Gray, Emma K., Hoskin, Peter, Khan, Mohammad M., Manetta, Caroline, McPhail, Neil J., O'Sullivan, Joe M., Parikh, Omi, Perna, Carla, Pezaro, Carmel J., Protheroe, Andrew S., Robinson, Angus J., Rudman, Sarah M., Sheehan, Denise J., Srihari, Narayanan N., Syndikus, Isabel, Tanguay, Jacob S., Thomas, Carys W., Vengalil, Salil, Wagstaff, John, Wylie, James P., Parmar, Mahesh K. B., Sydes, Matthew R.

“…Abiraterone acetate plus prednisolone (AAP) previously demonstrated improved survival in STAMPEDE, a multiarm, multistage platform trial in men starting…”
Get full text

Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial by Mason, Malcolm D, Clarke, Noel W, James, Nicholas D, Dearnaley, David P, Spears, Melissa R, Ritchie, Alastair W S, Attard, Gerhardt, Cross, William, Jones, Rob J, Parker, Christopher C, Russell, J Martin, Thalmann, George N, Schiavone, Francesca, Cassoly, Estelle, Matheson, David, Millman, Robin, Rentsch, Cyrill A, Barber, Jim, Gilson, Clare, Ibrahim, Azman, Logue, John, Lydon, Anna, Nikapota, Ashok D, O'Sullivan, Joe M, Porfiri, Emilio, Protheroe, Andrew, Srihari, Narayanan Nair, Tsang, David, Wagstaff, John, Wallace, Jan, Walmsley, Catherine, Parmar, Mahesh K B, Sydes, Matthew R

“…Purpose Systemic Therapy for Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy is a randomized controlled trial using a multiarm, multistage,…”
Get full text

Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial by James, Nicholas D, Spears, Melissa R, Clarke, Noel W, Dearnaley, David P, Mason, Malcolm D, Parker, Christopher C, Ritchie, Alastair W S, Russell, J Martin, Schiavone, Francesca, Attard, Gerhardt, de Bono, Johann S, Birtle, Alison, Engeler, Daniel S, Elliott, Tony, Matheson, David, O'Sullivan, Joe, Pudney, Delia, Srihari, Narayanan, Wallace, Jan, Barber, Jim, Syndikus, Isabel, Parmar, Mahesh K B, Sydes, Matthew R

“…The natural history of patients with newly diagnosed high-risk nonmetastatic (M0) prostate cancer receiving hormone therapy (HT) either alone or with…”
Get more information

A Comprehensive Vowel Space for Whispered Speech by Sharifzadeh, Hamid Reza, McLoughlin, Ian V, Russell, Martin J

“…Summary Whispered speech is a relatively common form of communications, used primarily to selectively exclude or include potential listeners from hearing a…”
Get full text

Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial by Attard, Gerhardt, Sydes, Matthew R, Mason, Malcolm D, Clarke, Noel W, Aebersold, Daniel, de Bono, Johann S, Dearnaley, David P, Parker, Chris C, Ritchie, Alastair W.S, Russell, J. Martin, Thalmann, George, Cassoly, Estelle, Millman, Robin, Matheson, David, Schiavone, Francesca, Spears, Melissa R, Parmar, Mahesh K.B, James, Nicholas D

“…Take Home Message There are compelling reasons to study the addition of both enzalutamide and abiraterone, in combination, to standard-of-care for…”
Get full text

Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial by Sydes, Matthew R, Parmar, Mahesh K B, Mason, Malcolm D, Clarke, Noel W, Amos, Claire, Anderson, John, de Bono, Johann, Dearnaley, David P, Dwyer, John, Green, Charlene, Jovic, Gordana, Ritchie, Alastair W S, Russell, J Martin, Sanders, Karen, Thalmann, George, James, Nicholas D

“…Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) is a randomized controlled trial that follows a novel…”
Get full text

Cost‐effectiveness of zoledronic acid and strontium‐89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate‐refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747) by Andronis, Lazaros, Goranitis, Ilias, Pirrie, Sarah, Pope, Ann, Barton, Darren, Collins, Stuart, Daunton, Adam, McLaren, Duncan, O'Sullivan, Joe M., Parker, Chris, Porfiri, Emilio, Staffurth, John, Stanley, Andrew, Wylie, James, Beesley, Sharon, Birtle, Alison, Brown, Janet E., Chakraborti, Prabir, Hussain, Syed A., Russell, J. Martin, Billingham, Lucinda J., James, Nicholas D.

“…Objective To evaluate the cost‐effectiveness of adding zoledronic acid or strontium‐89 to standard docetaxel chemotherapy for patients with castrate‐refractory…”
Get full text

Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial by James, Nicholas D, Ingleby, Fiona C, Clarke, Noel W, Amos, Claire L, Attard, Gerhardt, Brawley, Christopher D, Chowdhury, Simon, Cross, William, Dearnaley, David P, Gilbert, Duncan C, Gillessen, Silke, Jones, Robert J, Langley, Ruth E, Macnair, Archie, Malik, Zafar I, Mason, Malcolm D, Matheson, David J, Millman, Robin, Parker, Chris C, Rush, Hannah L, Russell, J Martin, Au, Carly, Ritchie, Alastair W S, Mestre, Ricardo Pereira, Ahmed, Imtiaz, Birtle, Alison J, Brock, Susannah J, Das, Prantik, Ford, Victoria A, Gray, Emma K, Hughes, Robert J, Manetta, Caroline B, McLaren, Duncan B, Nikapota, Ashok D, O'Sullivan, Joe M, Perna, Carla, Peedell, Clive, Protheroe, Andrew S, Sundar, Santhanam, Tanguay, Jacob S, Tolan, Shaun P, Wagstaff, John, Wallace, Jan B, Wylie, James P, Zarkar, Anjali, Parmar, Mahesh K B, Sydes, Matthew R

“…STAMPEDE previously reported adding upfront docetaxel improved overall survival for prostate cancer patients starting long-term androgen deprivation therapy…”
Get full text

Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial by Parker, Christopher C., Sydes, Matthew R., Mason, Malcolm D., Clarke, Noel W., Aebersold, Daniel, Bono, Johann S., Dearnaley, David P., Ritchie, Alastair W.S., Russell, J. Martin, Thalmann, George, Parmar, Mahesh K.B., James, Nicholas D.

Get full text

Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness by Woods, Beth S., Sideris, Eleftherios, Sydes, Matthew R., Gannon, Melissa R., Parmar, Mahesh K.B., Alzouebi, Mymoona, Attard, Gerhardt, Birtle, Alison J., Brock, Susannah, Cathomas, Richard, Chakraborti, Prabir R., Cook, Audrey, Cross, William R., Dearnaley, David P., Gale, Joanna, Gibbs, Stephanie, Graham, John D., Hughes, Robert, Jones, Rob J., Laing, Robert, Mason, Malcolm D., Matheson, David, McLaren, Duncan B., Millman, Robin, O'Sullivan, Joe M., Parikh, Omi, Parker, Christopher C., Peedell, Clive, Protheroe, Andrew, Ritchie, Alastair W.S., Robinson, Angus, Russell, J. Martin, Simms, Matthew S., Srihari, Narayanan N., Srinivasan, Rajaguru, Staffurth, John N., Sundar, Santhanam, Thalmann, George N., Tolan, Shaun, Tran, Anna T.H., Tsang, David, Wagstaff, John, James, Nicholas D., Sculpher, Mark J.

“…Results from large randomised controlled trials have shown that adding docetaxel to the standard of care (SOC) for men initiating hormone therapy for prostate…”
Get full text

A multiple-level linear/linear segmental HMM with a formant-based intermediate layer by Russell, Martin J., Jackson, Philip J.B.

“…A novel multi-level segmented HMM (MSHMM) is presented in which the relationship between symbolic (phonetic) and surface (acoustic) representations of speech…”
Get full text

Probabilistic-trajectory segmental HMMs by Holmes, W.J., Russell, M.J.

“…“Segmental hidden Markov models” (SHMMs) are intended to overcome important speech-modelling limitations of the conventional-HMM approach by representing…”
Get full text